Abemaciclib

The addition of abemaciclib to a nonsteroidal aromatase inhibitor prolonged median OS by more than a year among patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to data presented at ESMO Congress.

In this episode, VTE rate with abemaciclib higher in real-world setting; Enhertu extends progression-free survival in patient subgroup; FDA grants priority review to elacestrant for metastatic disease; and more.

Abemaciclib resulted in an approximately twofold higher venous thromboembolism rate in a real-world setting compared with clinical trials among patients with metastatic breast cancer, according to study results published in Cancer.

CHICAGO — Halle Moore, MD, director of breast medical oncology in the department of hematology and oncology at Cleveland Clinic Taussig Cancer Institute, spoke with Healio about findings from the ELAINE 2 study.

Results from a phase 2 study showed that abemaciclib in combination with letrozole shrunk or stabilized tumors in 75% of patients with recurrent or persistent estrogen receptor-positive, or ER-positive, endometrial cancer.

The FDA approved abemaciclib in combination with endocrine therapy for adjuvant treatment of certain patients with early breast cancer.

Healio spoke with Debu Tripathy, MD, about the use of targeted therapies in breast cancer.

The oncotype DX assay better predicted the benefits of chemotherapy among patients with HR-positive breast cancer and one to three positive lymph nodes, according to findings from the RxPonder study presented at the San Antonio Breast Cancer Symposium.

The virtual format of this year’s San Antonio Breast Cancer Symposium had its negatives, like missing discussions with colleagues, and its positives, according to Elias Obeid, MD, MPH.

At the virtual San Antonio Breast Cancer Symposium, researchers presented results from the monarchE and PENELOPE-B trials that investigated ways to “improve cure rates and decrease recurrence rates among women with high-risk breast cancer.”